QUOTED. 7 January. Kevin Thornal.
Hologic announced its second acquisition this week and plans to spend $230m for the privately held diagnostics maker BioTheranostics Inc to align its broader corporate focus on women’s health. See what Hologic’s division president of diagnostics, Kevin Thornal, said about the buy-out here.
“Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to accelerate growth, help physicians make more informed decisions and deliver more personalized treatment and better clinical outcomes for more women.” – Kevin Thornal, division president diagnostics, Hologic
Click here for a free trial of Medtech Insight